{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:26:08Z","timestamp":1791321968545,"version":"4.3.1"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T00:00:00Z","timestamp":1227571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p>Vasohibin\u20101 is a recently identified negative feedback inhibitor or suppressor of angiogenesis induced by vascular endothelial growth factor (VEGF)\u2010A. The status of vasohibin\u20101 in human breast carcinoma has not been examined. We examined 151 breast specimens including 98 cases of invasive ductal carcinoma (IDC), 12 of ductal carcinoma <jats:italic>in situ<\/jats:italic> (DCIS), 16 of fibroadenoma (FA), six of inflammatory lesion, nine of fibrocystic change and seven of non\u2010pathological breast tissue. We immunolocalized vasohibin\u20101 and compared its immunoreactivity to that of VEGF\u2010A, basic fibroblastic growth factor (bFGF), VEGF receptor 2 (Flk\u20101), CD31, CD34 and Ki\u201067\/MIB\u20101. The correlation of vasohibin\u20101 immunoreactivity with overall survival (OS), and disease\u2010free survival (DFS) of the patients with breast carcinoma was also evaluated. In addition, we evaluated Ki\u201067 and CD31, and Ki\u201067 and vasohibin\u20101 double\u2010immunostaining for further characterization of neovascularization. Vasohibin\u20101 was detected in endothelial cells of human breast and its immunodensity was significantly higher in IDC and inflammatory lesions than the other types (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00.001). In addition, a significant positive correlation was detected between vasohibin\u20101 and VEGF\u2010A, bFGF or Flk\u20101 (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00.001). There was also positive association<jats:italic>s<\/jats:italic> between vasohibin\u20101 and OS (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.004) and between vasohibin\u20101 and DFS (<jats:italic>P\u00a0\u2264\u00a00.001<\/jats:italic>) in carcinoma cases. Results of double\u2010immunostaining demonstrated the ratio of Ki\u201067\u2010positive cells among vasohibin\u20101\u2010positive endothelial cells (46.5%) was significantly higher than those among CD31\u2010positive cells (23.5%). This is the first study demonstrating the status of vasohibin\u20101 in human breast lesions, which indicates that vasohibin\u20101 is associated with neovascularization and may especially play important roles in the regulation of intratumoral angiogenesis in human breast cancer. (<jats:italic>Cancer Sci<\/jats:italic> 2009; 100: 88\u201394)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2008.01015.x","type":"journal-article","created":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T09:16:25Z","timestamp":1227604585000},"page":"88-94","source":"Crossref","is-referenced-by-count":78,"title":["Vasohibin\u20101 in human breast carcinoma: A potential negative feedback regulator of angiogenesis"],"prefix":"10.1111","volume":"100","author":[{"given":"Kentaro","family":"Tamaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Ohuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Sasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0195-27"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000252062.48280.61"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200421152"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.12.073"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23153"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.01.185"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016018617152"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0027"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00777.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101033240101"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.24.1875"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90982-6"},{"key":"e_1_2_6_14_2","first-page":"131","author":"Sobin LH","journal-title":"TNM Classification of Malignant Tumours"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1991.tb00229.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.04.176"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06214.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2004.03.017"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-1957"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1945::AID-CNCR11>3.0.CO;2-Y"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5858\/2004-128-893-NCOTBA","article-title":"Non\u2010invasive carcinoma of the breast: angiogenesis and cell proliferation","volume":"128","author":"Cao Y","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0796-811"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1994.tb02904.x"},{"issue":"3","key":"e_1_2_6_24_2","first-page":"591","article-title":"Immunohistochemical expression of heparin\u2010binding protein 17\/fibroblast growth factor\u2010binding protein\u20101 (HBp17\/FGFBP\u20101) as an angiogenic factor in head and neck tumorigenesis","volume":"17","author":"Begum S","year":"2007","journal-title":"Oncol Report"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.2174\/1566524033479465"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/386671a0"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-653"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.1988.Supplement_10.16"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000216747.66660.26"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1096\/fj.05-5046fje","article-title":"Vasohibin is up\u2010regulated by VEGF in the retina and suppress VEGF receptor 2 and retinal neovascularization","volume":"20","author":"Shen JK","year":"2006","journal-title":"FASEB J"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980729)77:3<455::AID-IJC23>3.0.CO;2-5"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022133219353"},{"key":"e_1_2_6_33_2","first-page":"609","article-title":"Angiogenesis of breast cancer","volume":"22","author":"Scneider BP","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34062"},{"key":"e_1_2_6_35_2","first-page":"4a","article-title":"The prognostic value of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and associations to first metastasis site in 1307 patients with primary breast cancer","volume":"20","author":"Linderholm B","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-suppl_1-43"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1796"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.098"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4645"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2008.01015.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2008.01015.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T09:13:11Z","timestamp":1697188391000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2008.01015.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1349-7006.2008.01015.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2008.01015.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}